NCT05641831 2026-01-02
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Thomas Jefferson University